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CD4+ count among HIV positive patients in
Hoima Regional Referral Hospital
Martina Nanteza1†, Jayne B Tusiime2†, Joan Kalyango1,3† and Arabat Kasangaki4*†Abstract
Background: The aim of this study was to determine the prevalence of Human Immune Virus (HIV) related oral
lesions and their association with Cluster of Differentiation 4 (CD4+) count among treatment naïve HIV positive patients.
Methods: This was a descriptive and analytical cross sectional study. Participants were 346 treatment naïve HIV positive
adult patients. These were consecutively recruited from Hoima Regional Referral hospital between March and April
2012. Data collection involved interviews, oral examinations and laboratory analysis.
Results: A total of 168(48.6%) participants had oral lesions. The four commonest lesions were oral candidiasis
(24.9%, CI = 20.6-29.7%), melanotic hyperpigmentation (17.3%, CI = 13.7-21.7%), kaposi sarcoma (9.3%, CI = 6.6-12.8%)
and Oral Hairy Leukoplakia (OHL) (5.5%, CI = 3.5-8.4%). There was significant association between oral candidiasis and
immunosuppression measured as CD4+ less than 350 cells/mm3 (OR = 2.69, CI = 1.608-4.502, p < 0.001). Oral candidiasis
was the only oral lesion significantly predictive of immunosuppression (OR = 2.56, CI = 1.52-4.30, p < 0.001) with a Positive
Predictive Value (PPV) of 48.2%, Negative Predictive Value (NPV) of 74.3%, 38.1% sensitivity and specificity of 81.4%.
Conclusion: Oral candidiasis can be considered as a marker for immunesuppression, making routine oral examinations
essential in the management of HIV positive patients.
Keywords: Oral candidiasis, Low CD4+ count, HIV positive patientsBackground
HIV is a major global health problem. Sub-Saharan Africa
continues to bear an inordinate share of the global HIV bur-
den with 23 million people living with HIV/AIDS residing
in this region [1]. Current HIV prevalence rates in Uganda
stand at 7.4% [2] Among the HIV-associated infections, oral
lesions have been recognized as prominent features since
the beginning of the epidemic and continue to be import-
ant. Approximately 40-50% of people who are HIV-positive
have been reported to have oral fungal, bacterial or viral
infections, which often occur early in the course of HIV
infection [3]. The occurrence of these oral lesions in HIV
infection reflects the immune status of the patient with
many being associated with reduced CD4+ T lymphocyte
cell count. Because of this, they can be used as entry or end-* Correspondence: arabat55@yahoo.com
†Equal contributors
4Department of Dentistry, Makerere University, P.O. Box 33019, Kampala, Uganda
Full list of author information is available at the end of the article
© 2014 Nanteza et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.points in therapy and vaccine trials as well as in staging and
classification systems [4,5]. They are thus not only import-
ant for their morbidity and mortality but also for their diag-
nostic value in monitoring the immune status of the patient.
In resource constrained settings, where routine access to
immunological monitoring is limited, oral lesions have
been suggested as useful aids that are complimentary to
regular CD4+ count assessment [6]. In such settings there-
fore, monitoring is typically clinical and immunological,
mainly as a result of financial and infrastructure con-
straints [7,8]. There are cardinal lesions that are strongly
associated with HIV and used internationally in the
disease staging. The prevalence of such lesions amongst
HIV positive individuals varies from region to region.
Agwu et al. [9] found a prevalence of 71% in south west-
ern Uganda, while Tirwome et al. [10] recorded a 72%
prevalence among HIV patients in several TASO clinics.
Given that disease patterns change over time, and differ
according to region studied its vital to know the currentl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ciation between the oral lesions and immunesuppres-
sion among HIV positive patients in Uganda is lacking.
The aim of this study therefore was to highlight the
prevalence of oral lesions among HIV positive patients,
in the long run expressing the oral disease burden
among HIV patients. The relationship between these le-
sions and the immune status of the patients was assessed
in order to show how, if coupled with immunological
monitoring, patients in resource limited settings can have
the disease properly staged, classified and managed.
Methods
Participants and study setting
This was a descriptive and analytical cross-sectional
study carried out from March to April 2012, in which
quantitative data collection methods were used. It was
carried out among consenting treatment naïve HIV posi-
tive male and female patients aged 18 years and above
attending Hoima Regional Referral hospital HIV clinic.
Patients who were too ill to participate in the interviews
and oral examinations were excluded. Participants (n =
346) were consecutively selected as they presented to
the clinic. Using an interviewer administered, standard
and pre-tested questionnaire, information on socio-
demographic characteristics; socio-behavioral factors;
experience with oral lesions, and their consequences
was collected. Information about history of systemic co-
morbidities, history of previous HIV oral lesions, and
prescribed medication was obtained from the patient’s
medical records.
Investigations
Oral examinations were carried out by a dental surgeon,
who was blinded to the clinical staging and CD4+ count
results of the patients. Patients were examined while
seated in a chair and in a well illuminated room. The extra
oral and perioral areas were examined first, followed by
intraoral tissues for any abnormalities. For better explor-
ation of the mouth, periodontal probes, dental explorers
and dental mirrors were used. Diagnosis of the oral lesions
was made using European Community (EC) clearing
house guidelines for presumptive diagnosis of oral le-
sions [11]. According to these guidelines, the lesions are
classified into 3 groups: those strongly associated with
HIV infection; those less commonly associated with
HIV infection; and those seen in, but not indicative of
HIV infection.
Lesions diagnosed were recorded into the World
Health Organization (WHO) recording form for oral le-
sions associated with HIV infection. The inner and
buccal surfaces of the lower incisors and the first two
molars were assessed for presence of plaque or calculus.
These were the lower incisors and the first two uppermolars, whose inner and buccal surfaces were respect-
ively examined. A photo atlas was developed to docu-
ment the lesions diagnosed during the study. The
clinical staging of new patients was done by the medical
doctors in the HIV clinic.
For the regular patients, the clinical staging was re-
trieved from the patient’s records. The blood samples
were obtained on the same day as the oral examinations
and their results were recorded onto each participant’s
questionnaire.
Data management and quality control
Pretested questionnaires were used in data collection
and were checked daily for consistency and complete-
ness before the data was entered into the computer.
Translation of the questionnaire into Runyakitara was done
to cater for participants not well conversant with English.
Data was entered in Epi data version 3.1, edited and cleaned
and then exported to STATA version 9 for analysis.
Data analysis
Descriptive analysis was used to summarize the partici-
pants’ characteristics using medians, percentages, fre-
quencies and interquartile ranges. Odds ratios at 95%
confidence intervals were used to measure association
between each of the predictor variables and presence of
oral lesions. Chi-square test with level of significance at
0.05 was used to test the significance of the association
between presence of oral lesions and the predictor vari-
ables. CD4+ was categorized into CD4+ <350 cells/mm3
and CD4+ ≥350 cells/mm3, with immune suppression be-
ing defined as CD4+ < 350 cells/mm3 [12]. Positive and
negative predictive values of the most common lesions for
CD4+ <350 cells/mm3 were computed. The sensitivity and
specificity of the commonest lesions to diagnose immune
suppression of <350 cells/mm3 were determined. Vari-
ables with p-value less than 0.2 at bivariate analysis were
considered for inclusion in the multiple logistic regression
models, with presence of oral lesions as the outcome.
With CD4+ as the main predictor, other predictors were
assessed for confounding and interaction.
Ethical considerations
Permission to carry out the study was sought from
Makerere University School of Medicine Research and
Ethics Committee, the Uganda National Council of
Science and Technology and Hoima hospital authorities.
Written informed consent was obtained from the partici-
pants, and confidentiality was assured by concealing the
patients’ names and using identification numbers on the
questionnaires. Participants diagnosed with different oral
lesions were treated in Hoima hospital and others who re-
quired further management were referred to the relevant
health units.
Nanteza et al. BMC Oral Health 2014, 14:143 Page 3 of 6
http://www.biomedcentral.com/1472-6831/14/143Results
Of the 346 consenting participants, 265(76.6%) were fe-
males and 81(23.4%) males (Table 1). The median age in
this study group was 33 years (IQR, 25–41). Of the par-
ticipants, 124(35.8%) had a history of regular alcohol
consumption and 25(7.2%) had a history of regular to-
bacco smoking. About 24 (7%) of the respondents said
they did not regularly brush their teeth, while 79(22.8%)
reported brushing more than once daily. More than half
of the respondents (53.2%, n = 184) reported never hav-
ing gone for a dental checkup, and 154 (44.5%) reported
going only when in discomfort. Most respondents had
CD4+ count greater than 350 cells/mm3 (88.1%, n = 296),
and majority of the respondents belonged to WHO stage
two, (73.0%, n = 252).
HIV associated oral lesions were observed in 48.6% (CI =
43.3-53.8%) (n = 168) respondents. Among the 346 respon-
dents, the four most common lesions were oral candidiasis,Table 1 Sociodemographic, sociobehavioral,
dentobehavioral and clinical characteristics of 346
participants from Hoima Regional Referral Hospital











Not often 24 6.9
Once daily 243 70.2
More than once daily 79 22.8
Dental visits
Never 184 53.2
Once a year 6 1.7
Every six months 2 0.6
When in discomfort 154 44.5








*CD4+ count values for 10 subjects missing.melanotic hyperpigmentation, Kaposi sarcoma and OHL,
in that order, as shown in Table 2 below. Oral candidiasis
was present in 86 (24.9%) of the respondents, with the
pseudomembranous subtype being the most prevalent and
present among 42 respondents (12%). Melanotic hyperpig-
mentation was observed among 60 patients (17.3%, CI =
13.7-21.7%), whereas kaposi sarcoma was diagnosed among
32 participants (9.3% CI = 6.6-12.8%). Oral hairy leukopla-
kia was the least prevalent at 5.5% (n = 19, CI = 3.5-8.4%).
At bivariate analysis, CD4+ count of less than 350
cells/mm3, was found to be significantly associated with
presence of oral candidiasis (OR = 2.691, p < 0.001,CI =
1.608-4.502). In the multivariate model, CD4+ count,
problems with oral functions and WHO stage were sig-
nificantly associated with the presence of oral candidiasis
as shown in Table 3.
In the multivariate model, after analysis, we did not
find any confounding by any of the dependent variables,
and neither was there any interaction between them.
Candidiasis was the only significant predictor of immune
suppression measured as CD4 < 350 cells/mm3, (OR =
2.56, 1.52-4.30, p < 0.001), (Table 4) The PPV of OHL,
kaposi sarcoma, melanotic hyperpigmentation and can-
didiasis were 47.4%, 41.9%, 32.2% and 48.2% respectively.
The NPV of OHL, kaposi sarcoma, melanotic hyperpig-
mentation, and candidiasis were 69.7%, 69.8%, 68.9%,
and 74.3% respectively. The sensitivity values were 8.6%,
12.4%,18.1% and 38.1% for OHL, kaposi sarcoma, melan-
otic hyperpigmentation and candidiasis respectively.
Values for specificity were 95.7%, 92.2%, 82.7% and 81.4%Table 2 Prevalence of oral lesions among 346 Hoima
hospital respondents
Oral lesion Frequency Percentage 95% CI
Any oral lesion 168 48.6 43.3-53.8




Erythematous candidiasis 29 8.4 5.9-11.8
Angular cheilitis 15 4.3 2.7-7.0
Oral hairy leukoplakia 19 5.5 3.5-8.4
Kaposi sarcoma 32 9.3 6.6-12.8
Melanotic hyperpigmentation 60 17.3 13.7-21.7
Linear gingival erythema 7 2.0 0.9-4.1
Herpes simplex 6 1.7 0.8-3.7
Recurrent apthous ulcers 5 1.5 0.6-3.3
Xerostomia 5 1.5 0.6-3.3
Salivary gland enlargement 13 3.8 2.2-6.3
Rampant caries 15 4.3 2.7-7.0
Calculus/plaque deposits 18 5.2 3.3-8.1
Table 3 Results of multivariate analysis of factors
associated with the presence of oral candidiasis
Variable OR p-value 95% CI
CD4+ 0.997 <0.001 0.995-0.999
Problem with oral functions
None 1.000
Chewing 7.389 <0.001 3.391-16.102
WHO stage
Stage 1 1.000
Stage 3 3.803 0.025 1.182-12.240
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and candidiasis respectively.
Discussion
Prevalence of oral lesions
Since the beginning of AIDS epidemic, developing coun-
tries have experienced difficulties in implementing appro-
priate, inexpensive, and efficient HIV laboratory diagnostic
techniques to aid in the epidemiological assessment and
control of HIV infection. Studies have been conducted
elsewhere for association of oral manifestations with abso-
lute CD4 lymphocyte counts [13-15]. However, on doing a
comprehensive literature search, there were no Ugandan
studies for association of oral manifestations with CD4+
count. Hence an attempt was made in this study towards
the correlation of oral manifestations with CD4+ count.
About five in every ten HIV patients in this study had
oral lesions. The prevalence of oral lesions found in this
study population was in agreement with the documented
range of 30–80% seen in developing countries [16-19]
and similar to findings from another study in Uganda
[17]. It is however relatively lower than previously re-
ported results from other studies done in different parts
of Uganda where prevalence rates as high as 73.2% and
72% were found [9,10]. This discrepancy is probably due
to the fact that there has been increased support from
government and donor agencies, and better strategies
for management of HIV over the years.
Oral candidiasis was the commonest lesion observed
in this study population, agreeing with findings by
Bodhade et al. (39.3%), Kardpon et al. (55%), Adrogubangba
et al. (33.3%) and Allan et al. (17.7%) [12,15,20,21]. The
pseudomembranous subtype was the commonest, just asTable 4 Association of oral lesions with immune suppression
Oral lesion OR 95% CI p-va
OHL 1.79 0.68-4.67 0.2
Kaposi sarcoma 1.48 0.67-3.27 0.3
Melanotic hyper pigmentation 0.96 0.51-1.81 0.8
Candidiasis 2.56 1.52-4.30 <0.0was observed in south western Uganda (Table 2). Melanotic
hyperpigmentation, although classified as a lesion less com-
monly associated with HIV, was the second most prevalent
in this study. As the study group comprised of treatment
naïve patients, the probability that this high prevalence was
due to effects of antiretroviral therapy is very small. From
their records no participants had previously been staged as
stage four patients though surprisingly, Kaposi sarcoma
which designates an individual to WHO stage four of HIV
disease, was found in 32 (9.3%) of the participants. This ex-
poses the discrepancies that occur in staging, and ultim-
ately in management of HIV patients. Such discrepancies
are more pronounced in resource limited settings where
access to routine immunological monitoring is limited.
Oral hairy leukoplakia had a low prevalence in this study,
(5.5%, n = 19) probably due to the fact that definitive diag-
nosis requires demonstration of Epstein- Barr virus, which
wasn’t conducted in this study and might have been a
source of potential misclassification.
Oral candidiasis in the prognosis of the disease
Findings showed that individuals under WHO stage
three are almost 4 times as likely as individuals in stage
one to develop oral candidiasis (Table 3). Oral candidia-
sis is currently being used to stage patients as stage three
under the WHO clinical staging system, making these
findings scientifically sound. In this study, HIV positive
patients with difficulty in chewing are seven times more
likely to have oral candidiasis than those without any
difficulty in chewing. When a comprehensive dental his-
tory is taken, it is possible to elicit such symptoms,
which when followed with an oral examination will aid
in the identification and diagnosis of oral lesions. The
oral lesions are in turn used to diagnose and monitor
immunesuppression.
Association between oral lesions and CD4+ count less
than 350 cells/mm3
Oral candidiasis was the only lesion found to have a sig-
nificant association with CD4+ count of less than 350
cells/mm3, (OR = 2.691, p < 0.001, CI = 1.608–4.502). Thus
in this study, immunosuppressed individuals were almost
thrice as likely to have oral candidiasis as their im-
mune competent counterparts. In addition, oral can-
didiasis was the only lesion significantly predictive of
immunesuppression in this study (Table 4). The(CD4 < 350 cells/mm3)
lue PPV NPV Sensitivity Specificity
38 47.4 69.7 8.6 95.7
34 41.9 69.8 12.4 92.2
96 32.2 68.9 18.1 82.7
01 48.2 74.3 38.1 81.4
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are thrice as likely to be immunosuppressed as those
without candidiasis. Therefore, oral candidiasis can be
used as an index for immunosuppression depicted by
CD4+ less than 350 cells in this study population.
These findings can be projected to other resource
constrained settings, which makes routine oral exami-
nations an essential part of management of HIV pa-
tients in these settings.
PPVs for oral manifestations to CD4+ less than 350
cells/mm3 were in a low range from 32.2% for melanotic
hyperpigmentation to 48.2% for candidiasis (Table 4).
Thus, with oral candidiasis as a test, forty eight (48) out
of a hundred (100) HIV patients diagnosed as beingim-
munosuppressed will truly be immunosuppressed. This
value is much lower than that from studies by Patton
et al. (60.3%) and Glick et al. (69.9%) [22,23] owing to
the low prevalence of immunosuppression in this study.
The range for NPV was from 68.9% for melanotic hyper-
pigmentation to 74.3% for oral candidiasis Because the
prevalence of immunosuppression in this population
was low, the high NPV value of 74.3% for oral candidia-
sis makes it a not very informative test as regards to
diagnosing the immunosuppression. Oral hairy leukopla-
kia had the highest specificity, of 95.7%. This means that
when used as a test for immunesuppression, the likeli-
hood for the occurrence of false positive results is low.
As is already the practice, oral hairy leukoplakia is being
utilized in patient staging. What these results emphasize
is the importance of oral examinations during routine
patient management.
Oral candidiasis had the highest sensitivity of 38.1%.
Thus if oral candidiasis is used as a test, the proportion
of individuals that would be correctly classified as im-
munosuppressed would be 68%, making candidiasis a
fairly good test for the diagnosis of immunosuppression
in the study population. Generally, the presence of oral
candidiasis should serve to herald the possibility of a
compromised immunity amongst HIV patients, thus
making oral examinations vital and beneficial towards
the management of the patients.Limitations, conclusions and recommendations
Diagnosis of the oral lesions was solely based on clinical
findings, and no definitive diagnostic tests were per-
formed. This might have introduced measurement bias
into the study, in the form of non differential misclassi-
fication bias. However, the effect of this is likely to be
minimal, as the diagnosis of the oral lesions followed
an internationally accepted and recognized standard set
of guidelines, the EC Clearing House guidelines. In
addition, the significant odds ratios seen are actually
true effect measures.The study indicates that almost half in every one
hundred study participants had an oral lesion, alone or
in combination with other types, which is a moderately
high rate.
The study demonstrated the possibility of oral candidia-
sis as an index to predict immunosuppression in resource
limited settings with no access to regular CD4+ count
monitoring. However to incorporate it as an index, certain
regional parameters and research studies that employ
rigorous research methodologies need to be done. There
is a need to compare the results of various cross-sectional
studies, and more longitudinal studies are required to
formulate oral lesion indices that can help as markers for
HIV-related immune suppression.
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